ストックスクリーナーアプリを入手
1,196.03
0.86%
10.16
プレマーケット:
1208.79
12.76
+1.07%
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly (NYSE:LLY) climbs into the spotlight as weight-loss drug demand runs hot - Kalkine Media
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide - NewsNation
Caxton Associates LLP Has $1.40 Million Stock Position in Eli Lilly and Company $LLY - InsuranceNewsNet
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? - The Motley Fool
Eli Lilly (NYSE:LLY): High-Growth Stock with Strong Technical and Fundamental Momentum - ChartMill
Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts - Yahoo Finance
Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO - Bloomberg.com
Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads - Law360
Novo Nordisk Sues Eli Lilly Over Misleading Ads - Intellectia AI
Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug Advertising - Yahoo Finance
Novo Nordisk seeks preliminary injunction days after suing Eli Lilly - MobiHealthNews
Novo Nordisk Seeks Pause on Eli Lilly’s Weight Loss Drug Ads - Bloomberg Law News
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal - Endpoints News
Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads - PharmaLive
Novo Nordisk seeks injunction to block Eli Lilly weight loss drug ads - Yahoo Finance
Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race - Stocktwits
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads - Yahoo Finance
The legal battle continues – Novo now seeks a temporary ban on Eli Lilly's advertisements - medwatch.com
This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly - Forbes
Novo Nordisk seeks court order to halt Eli Lilly drug ads - Investing.com Nigeria
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads - Yahoo Finance UK
LLY|Eli Lilly and Co|Price:1196.030|Chg%:+10.490 - TradingKey
Novo Investors: Lawsuit against Eli Lilly is apt - medwatch.com
Eli Lilly stock holds after 2025 revenue and profit growth - Ad-hoc-news.de
Novo Nordisk’s fight against Eli Lilly has gone legal: A top lawyer evaluates the case - Business Post
Eli Lilly and Company Price Today | XLLY Live Price, Chart & Market Cap - OKX
Eli Lilly Reports Positive Results from Two Phase III Trials | PharmExec - Pharmaceutical Executive
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Advertising Claims - Law Commentary
Lilly's Next-Generation Obesity Shot Clears Another Hurdle - Yahoo Finance UK
Eli Lilly (NYSE:LLY) Shapes the Healthcare Earnings Narrative - Kalkine Media
Lilly Targets Early 2027 Filing for Next Obesity Drug - Yahoo Finance
Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing - Yahoo Finance
Lilly, with new data, to seek FDA approval of obesity drug retatrutide - BioPharma Dive
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application - Reuters
Lilly to file for next-gen obesity drug approval in early 2027 - Yahoo Finance
Eli Lilly (NYSE:LLY) Growth & Technical Setup Signal A Key Market Test - Kalkine Media
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data - BioSpace
Lilly Endowment reports 90.4M Eli Lilly (LLY) shares, a 9.6% stake - Stock Titan
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - Yahoo Finance UK
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average - Forbes
Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors - simplywall.st
Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads - Stocktwits
Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle - Bloomberg.com
Eli Lilly (LLY) Advances Next-Gen Weight-Loss Therapy with Promi - GuruFocus
Eli Lilly presents positive safety data but postpones weight-loss candidate application - medwatch.com
Eli Lilly to File FDA Approval for Retatrutide in 2027 After Five Positive Phase 3 Trials - MLQ.ai
Eli Lilly and Co.'s next-generation obesity drug has had its market application delayed until 2027. - 富途牛牛
Eli Lilly (LLY) Reports Positive Phase 3 Trial Results for Retat - GuruFocus
Eli Lilly to seek obesity drug approval in Q1 2027 - Breakingthenews.net
Eli Lilly to seek approval for powerful new obe... - Pluang
Lilly’s retatrutide meets endpoints in two phase 3 obesity trials - Investing.com
New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit - STAT
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data - WSJ
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C - Eli Lilly and Company
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials - CNBC
Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup - ChartMill
Eli Lilly and Company (LLY) Stock Forecasts - Yahoo Finance
Novo Nordisk Sues Eli Lilly Over Wegovy and Mounjaro Obesity Drug Ads - 동아사이언스
Eli Lilly (LLY) Launches Kisunla As It Expands Its Neuroscience Push - simplywall.st
Watch Lilly’s Next-Generation Obesity Shot Clears Another Hurdle - Bloomberg.com
1.59%
0.72%
大文字化:
|
ボリューム (24 時間):